Table 1. Effect of BBT-877 treatment on physiological parameters of STZ-induced diabetic mice.

Characteristic	CV	SV	S108	S308	S908	S10L
Body weight (g)	26.9 ± 0.7	23.5 ± 0.4†	25.0 ± 0.4	24.4 ± 0.4	24.5± 0.4	25.0 ± 0.3
Kidney weight (mg)	297.3 ± 8.5	287.7 ± 5.8	272.8 ± 10.3	286.0 ± 11.1	283.4 ± 6.3	292.8 ±8.7
Liver weight (mg)	1105± 40	1385 ± 59†	1255 ± 48	1157 ± 57‡	1219 ± 46‡	1227 ± 48‡
Spleen weight (mg)	54.2 ± 3.16	55.4 ± 3.8	49.3 ± 1.9	47.4 ± 2.1	54.3 ± 2.4	48.4 ± 1.0
Food intake (gig per day)	0.19 ± 0.02	0.30 ± 0.03†	0.29 ± 0 .03	0.28 ± 0.03	0.26 ± 0.03	0.31 ± 0.03
Water intake (m/lg per day)	0.014 ± 0.0	0.064 ± 0.0†	0.045 ± 0.1p = 0.08	0.044 ± 0.0	0.039 ± 0.0‡	0.044 ± 0.0‡
Urine volume (ml/g per day)	0.046 ± 0.0	0.501 ± 0.1†	0.282 ± 0.1p = 0.08	0.270 ± 0.1p = 0.07	0.252 ± 0.1‡	0.329 ± 0.1
Albumin/creatinine ratio (μg/mg)	6.87 ± 0.5	31,94 ± 2.9†	21.27 ± 3.4‡	21.19 ± 4.3p = 0.06	19.36± 3.5‡	25.66 ± 3.6

Albumin/creatinine ratio was measured at 4 weeks; other parameters were measured at 8 weeks. Data are displayed as mean ± SEM. Abbreviations: STZ: streptozotocin; HbA1c: glycosylated hemoglobin; CV: control-vehicle; SV: STZ-vehicle; S10B: STZ-10 mg BBT-877; S30B: STZ-30 mg BBT-877; S90B: STZ-90 mg BBT-877; S10L: STZ-10 mg Losartan. ^†p < 0.01 vs. CV; ^‡p < 0.05 vs. SV, noted p values are vs. SV (n = 8−10).